EUVIMEDEUVIMED entdecken
Crossref

Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates

Dian Xiao, Lianqi Liu, Fei Xie, Jingwen Dong, Yanming Wang, Xin Xu, Wu Zhong iD, Hongbin Deng, Xinbo Zhou iD, Song Li

Angewandte Chemie International Edition · 15.04.2024 · 63 (16)

DOI: 10.1002/anie.202310318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 06.03.2024. Verfasst von Dian Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing antibody–drug conjugate (ADC) linkers, whether cleavable or non‐cleavable, are designed to release highly toxic payloads or payload derivatives upon internalisation of the ADCs into cells. However, clinical studies have shown that only 99 % of ADCs are nonspecifically distributed in healthy tissue cells, thus inevitably leading to off‐target toxicity. Herein, we describe an intelligent tumour‐specific linker strategy to address these limitations. A tumour‐specific linker is constructed by introducing a hypoxia‐activated azobenzene group as a toxicity controller. We show that this azobenzene‐based linker is non‐cleavable in healthy tissues (O 2 >10 %), and the corresponding payload derivative, cysteine‐appended azobenzene‐linker–monomethyl auristatin E (MMAE), can serve as a safe prodrug to mask the toxicity of MMAE (switched off). Upon exposure to the hypoxic tumour microenvironment (O 2

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunoconjugatesNeoplasmsHumansAzo CompoundsCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

Antibody–drug conjugatesazobenzene-based linkershypoxia

Substanzen

Antineoplastic AgentsImmunoconjugatesazobenzeneAzo Compounds

Autor:innen und Institutionen

  • National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.

ORCID-Profile: Wu Zhong, Xinbo Zhou

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Xiao, D., Liu, L., Xie, F., Dong, J., Wang, Y., Xu, X., Zhong, W., Deng, H., Zhou, X., & Li, S. (2024). Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates. Angewandte Chemie International Edition, 63(16). https://doi.org/10.1002/anie.202310318

Vancouver

Xiao D, Liu L, Xie F, Dong J, Wang Y, Xu X, et al. Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates. Angewandte Chemie International Edition. 2024;63(16). doi:10.1002/anie.202310318

BibTeX
@article{Xiao2024,
  author = {Xiao, Dian and Liu, Lianqi and Xie, Fei and Dong, Jingwen and Wang, Yanming and Xu, Xin and Zhong, Wu and Deng, Hongbin and Zhou, Xinbo and Li, Song},
  title = {Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  volume = {63},
  number = {16},
  doi = {10.1002/anie.202310318}
}
Kostenlos starten →